<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="63699">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01821937</url>
  </required_header>
  <id_info>
    <org_study_id>1220.52</org_study_id>
    <nct_id>NCT01821937</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Faldaprevir of Soft Capsule</brief_title>
  <official_title>Pharmacokinetics of Single and Multiple Oral Doses of 120 mg and 240 mg BI 201335 in Healthy Chinese Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the trial is to assess the bioavailability of Faldaprevir soft capsule with
      single oral dose and multiple oral doses  in Chinese subjects
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Single dose:AUC,1 (area under the concentration-time curve of the analyte in plasma over a uniform dosing interval  after administration of the first dose)</measure>
    <time_frame>up to 8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Single dose:AUC0- (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)</measure>
    <time_frame>up to 8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Single dose:AUCtz- (the percentage of the AUC 0- that is obtained by extrapolation)</measure>
    <time_frame>up to 8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Single dose:z (terminal rate constant in plasma)</measure>
    <time_frame>up to 8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Single dose: t1/2 (terminal half-life of the analyte in plasma)</measure>
    <time_frame>up to 8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Single dose: tz (time of last measurable concentration of the analyte in plasma</measure>
    <time_frame>up to 8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Single dose: MRTpo (mean residence time of the analyte in the body after po administration)</measure>
    <time_frame>up to 8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Single dose:CL/F (apparent clearance of the analyte in plasma following po administration)</measure>
    <time_frame>up to 8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Single dose:Vz/F (apparent volume of distribution during the terminal phase z following an po administration)</measure>
    <time_frame>up to 8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple Dose:Cmin,ss (minimum concentration of the analyte in plasma at steady state over a uniform dosing interval )</measure>
    <time_frame>up to 8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple Dose:z,ss (terminal rate constant in plasma at steady state)</measure>
    <time_frame>up to 8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple Dose: MRTpo,ss (mean residence time of the analyte in the body at steady state after po administration)</measure>
    <time_frame>up to 8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple Dose:CL/F,ss (apparent clearance of the analyte in the plasma at steady state following po multiple dose administration)</measure>
    <time_frame>up to 8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple Dose:Vz/F,ss (apparent volume of distribution during the terminal phase z at steady state following po administration)</measure>
    <time_frame>up to 8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple Dose:Cpre,N (predose concentration of the analyte in plasma immediately before administration of the Nth dose after N-1 doses were administered)</measure>
    <time_frame>up to 8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple Dose: tmax(,N) (time from last dosing to maximum concentration of the analyte in plasma after administration of N doses)</measure>
    <time_frame>up to 8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple Dose:In addition, the accumulation ratios (RA, Cmax, based on Cmax; RA, AUC, based on AUC0-) and the linearity index (LI) of the analyte in plasma following ten doses in healthy volunteers over a uniform dosing interval  will be calculated.</measure>
    <time_frame>up to 8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple Dose: Cmax,ss(maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval )</measure>
    <time_frame>up to 8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple Dose: AUC,ss (area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval )</measure>
    <time_frame>up to 8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Single dose: Cmax (maximum measured concentration of the analyte in plasma)</measure>
    <time_frame>up to 8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Single Dose:AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable concentration at tz) (if applicable)</measure>
    <time_frame>up to 8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple Dose:t1/2,ss (terminal half-life of the analyte in plasma at steady state) (if applicable)</measure>
    <time_frame>up to 8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple Dose:tmax,ss (time from last dosing to maximum concentration of the analyte in plasma at steady state)</measure>
    <time_frame>up to 8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>faldaprevir(high dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 subjects (approximate sex ration: 1:1) will be assigned to trial by single and multiple dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Faldaprevir(low dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 subjects (approximate sex ration: 1:1) will be assigned to trial by single and multiple dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>faldaprevir(high dose)</intervention_name>
    <description>faldaprevir(high dose) will be taken by 1 day single use and 10 days multiple use. the subjects will be assigned to high dose treatment in random order</description>
    <arm_group_label>faldaprevir(high dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Faldaprevir(low dose)</intervention_name>
    <description>faldaprevir(low dose) will be taken by 1 day single use and 10 days multiple use. the subjects will be assigned to low dose treatment in random order</description>
    <arm_group_label>Faldaprevir(low dose)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        Healthy male and female subjects

        Exclusion criteria:

        Any relevant deviation from healthy conditionsAny relevant deviation from healthy
        conditions
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1220.52.86001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 8, 2013</lastchanged_date>
  <firstreceived_date>March 25, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
